¾ÆÀ̵ðÀúÀå
ȸ¿ø°¡ÀÔ   id/pwã±â

 
 Home > û±¸½É»çÁ¤º¸¹æ > û±¸½É»ç FAQ  
Vedolizumab ÁÖ»çÁ¦(Ç°¸í: ŲÅÚ·¹½ºÁÖ)ÀÇ ±Þ¿©±âÁØÀÌ ±Ã±ÝÇÕ´Ï´Ù
°ü¸®ÀÚ 2017/08/08 1004

Vedolizumab ÁÖ»çÁ¦(Ç°¸í: ŲÅÚ·¹½ºÁÖ)

¡á °í½Ã ½Å¼³ Àüü³»¿ë
1. Çã°¡»çÇ× ¹üÀ§ ³»¿¡¼­ ¾Æ·¡¿Í °°Àº ±âÁØÀ¸·Î Åõ¿© ½Ã ¿ä¾ç±Þ¿©¸¦ ÀÎÁ¤Çϸç, µ¿ ÀÎÁ¤±âÁØ ÀÌ¿Ü¿¡´Â ¾à°ª Àü¾×À» ȯÀÚ°¡ ºÎ´ãÅä·Ï ÇÔ.
- ¾Æ ·¡ -
°¡. ±Ë¾ç¼º ´ëÀå¿°
1) Åõ¿©´ë»ó
1Á¾ ÀÌ»óÀÇ Á¾¾ç±«»çÀÎÀÚ ¾ËÆÄ(Tumor Necrosis Factor-¥á) ¾ïÁ¦Á¦ Ä¡·á¿¡ ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê°Å³ª, ¹ÝÀÀÀÌ ¾ø¾îÁö°Å³ª, ¶Ç´Â ³»¾à¼ºÀÌ ¾ø´Â Áߵ-ÁßÁõÀÇ ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ

¡Ø Áߵ-ÁßÁõÀÇ ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ
: ¾Æ·¡ÀÇ Á¡¼ö¸¦ ÇÕ»êÇÏ¿© Áߵ-ÁßÁõ ±Ë¾ç¼º ´ëÀå¿° ¿©ºÎ¸¦ ÆÇÁ¤(Mayo score 6 to 12 and Endoscopy subscore ¡Ã 2)

¡Ø ±Ë¾ç¼º´ëÀå¿° È°µ¿Æò°¡¸¦ À§ÇÑ ¸ÞÀÌ¿ä Á¡¼ö½Ã½ºÅÛ(Mayo Scoring System for Assessment of Ulcerative Colitis Activity)
¹èº¯ºóµµ(Stool frequency)
0 = Normal no. of stools for this patient
1 = 1 to 2 stools more than normal
2 = 3 to 4 stools more than normal
3 = 5 or more stools more than normal
Subscore, 0 to 3
Á÷ÀåÃâÇ÷(Rectal bleeding)
0 = No blood seen
1 = Streaks of blood with stool less than half the time
2 = Obvious blood with stool most of the time
3 = Blood alone passes
Subscore, 0 to 3
³»½Ã°æ °á°ú(Findings on endoscopy)
0 = Normal or inactive disease
1 = Mild disease (erythema, decreased vascular pattern, mild friability)
2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions)
3 = Severe disease (spontaneous bleeding, ulceration)
Subscore, 0 to 3
ÀÇ»çÀÇ Á¾ÇÕÆò°¡(Physician¡¯s global assessment)
0 = Normal
1 = Mild disease
2 = Moderate disease
3 = Severe disease
Subscore, 0 to 3

2) Æò°¡¹æ¹ý
µ¿ ¾àÁ¦¸¦ 14ÁÖ Åõ¾à ÈÄ ´ÙÀ½ °¢ È£ÀÇ Á¶°ÇÀ» ¸ðµÎ ÃæÁ·ÇÏ´Â °æ¿ì Áö¼ÓÀûÀÎ Åõ¿©¸¦ ÀÎÁ¤ÇÔ.
- ´Ù À½ -
°¡) Mayo score°¡ ÃÖÃÊ Åõ¿©½ÃÁ¡ º¸´Ù 30% ÀÌ»ó °¨¼ÒÇÏ°í 3Á¡ ÀÌ»ó °¨¼ÒÇÑ °æ¿ì
³ª) Rectal bleeding subscore 1Á¡ ÀÌ»ó °¨¼Ò ¶Ç´Â Rectal bleeding subscore 0Á¡ ¶Ç´Â 1Á¡ÀÎ °æ¿ì

³ª. Å©·Ðº´
1) Åõ¿©´ë»ó
1Á¾ ÀÌ»óÀÇ Á¾¾ç±«»çÀÎÀÚ ¾ËÆÄ(Tumor Necrosis Factor-¥á) ¾ïÁ¦Á¦ Ä¡·á¿¡ ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê°Å³ª, ¹ÝÀÀÀÌ ¾ø¾îÁö°Å³ª, ¶Ç´Â ³»¾à¼ºÀÌ ¾ø´Â Áߵ-ÁßÁõÀÇ È°¼ºÅ©·Ðº´ (Å©·Ðº´È°¼ºµµ(CDAI) 220ÀÌ»ó)

¡Ø Å©·Ðº´ È°¼ºµµ(CDAI)
: ¾Æ·¡ÀÇ Á¡¼ö¸¦ ÇÕ»êÇÏ¿© È°¼ºµµ(CDAI: Crohn's Disease Activity Index)¸¦ ÀÎÀ§ÀûÀ¸·Î Á¤ÇÏ¿© È°µ¿¼º ¿©ºÎ¸¦ ÆÇÁ¤
(1) 1ÁÖ¿¡ ¼³»çȽ¼öÀÇ ÇÕ ¡¿ 2
(2) 1ÁÖ¿¡ º¹ÅëÀÇ Á¤µµÀÇ ÇÕ(Áõ»ó¾øÀ½=0, °æÁõ=1, ÁßµîÁõ=2, ÁßÁõ=3) x 5
(3) 1ÁÖ¿¡ ÀϹÝÀûÀ¸·Î Àü½Å ¾È³ç°¨ÀÇ ÇÕ(ÁÁÀ½=0, Æò±ÕÀÌÇÏ=1, ³ª»Ý=2, ¸Å¿ì ³ª»Ý=3, ±Øµµ·Î ³ª»Ý=4) ¡¿ 7
(4) ´ÙÀ½ 6Ç׸ñ Áß È¯ÀÚ°¡ ÇöÀç ³ªÅ¸³»´Â ÇØ´ç Ç׸ñÀÇ °³¼ö ¡¿ 20
(°¡) °üÀý¿°/°üÀýÅë
(³ª) ȫä¿°/Æ÷µµ¸·¿°
(´Ù) °áÀý¼ºÈ«¹Ý, ±«Àú¼º³óÇÇÁõ, ¾ÆÇÁŸ¼º±¸³»¿°
(¶ó) Ç×¹®¿­»ó, ´©°ø ȤÀº ³ó¾ç
(¸¶) ±âŸ ´©°ø
(¹Ù) Áö³­ÁÖ°£ 37.8¡ÉÀÌ»ó ¹ß¿­
(5) ¼³»ç ¶§¹®¿¡ ¸¶¾à¼º Áö»çÁ¦ º¹¿ë½Ã ¡¿ 30
(6) º¹ºÎÁ¾±«(¾øÀ½=0, ÀǽÉ=2, È®Á¤Àû=5) ¡¿ 10
(7) Ç츶ÅäÅ©¸®Æ®(³²:47, ¿©:42-ȯÀÚ HctÄ¡) ¡¿ 6
(8) ((Ç¥ÁØüÁß - ȯÀÚüÁß)/Ç¥ÁØüÁß) ¡¿ 100(%)

2) Æò°¡¹æ¹ý
ù Åõ¾à ÈÄ 14ÁÖ À̳»¿¡ CDAI°¡ 70Á¡ ÀÌ»ó °¨¼Ò ¶Ç´Â ÃÑ CDAI scoreÀÇ 25% ÀÌ»ó °¨¼ÒµÈ °æ¿ì¿¡ ÇÑÇÏ¿© À¯Áö¿ä¹ýÀ» ÀÎÁ¤ÇÔ.

2. µ¿ ¾àÁ¦¿¡ È¿°ú°¡ ¾ø°Å³ª ºÎÀÛ¿ëÀ¸·Î Åõ¾àÀ» Áö¼ÓÇÒ ¼ö ¾ø¾î ÀÌÀü¿¡ Åõ¿©ÇÑ ÀûÀÌ ¾ø´Â ´Ù¸¥ TNF-¥á inhibitor (Adalimumab, Infliximab, Golimumab ÁÖ»çÁ¦)·Î ±³Ã¼Åõ¿©(Switch)ÇÏ´Â °æ¿ì ±Þ¿©¸¦ ÀÎÁ¤Çϸç, ÀÌ °æ¿ì¿¡´Â ±³Ã¼Åõ¿©¿¡ ´ëÇÑ Åõ¿©¼Ò°ß¼­¸¦ ÷ºÎÇÏ¿©¾ß ÇÔ.

¡á °í½Ã ½Å¼³ °í½Ã¹øÈ£(½ÃÇàÀÏÀÚ)
°í½Ã Á¦2017-136È£ <2017.08.01>